The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...

In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from the panel’s planned meeting next week are confirming many industry ...

Robert F. Kennedy Jr. dismissed all members of the CDC’s Advisory Committee on Immunization Practices, which recommends which ...

F or the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing ...

The S&P 500 added 0.9% on Monday, June 16, as investors absorbed the possibility of cooling geopolitical tensions and looked ...